You do realize what this means, don't you? Soon, U.S. pharmaceutical companies will find themselves at a competative disadvantage. Which means that in short order, their bought and paid for representatives in Congress will be singing the praises of cannabis-based medicines.
At least the ones that are produce by a patentable synthesis process.